Virtual diet coaching aims to boost nutrition after stomach cancer surgery
NCT ID NCT05203627
First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times
Summary
This study tests a telehealth program designed to help people improve their diet and quality of life after surgery for stomach or esophagus cancer. About 53 patients who have had curative surgery will receive virtual sessions with diet support. The goal is to see if the program is practical and helpful for managing nutrition after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Telehealth diet support sessions
- What this could lead to
- If successful, this program could provide a practical way to help patients eat better and feel better after stomach cancer surgery.
- What could go wrong
- This is a small, early feasibility study with only 53 participants, so results may not apply to everyone. It tests whether the program is practical, not whether it definitively improves health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
53 people
The number who actually took part.
- Started
-
Jan 2020
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The ability to understand English or Spanish. * Undergone curative intent surgery for gastric or gastroesophageal (GE) junction cancer. * Began oral intake within the past month. * Aged 21 years and older. * Able to participate in telehealth sessions. * This study will be conducted in patients aged 21 years or older who have undergone curative intent surgery for gastric or GE junction cancer. * Age criterion for this trial is based on the National Institute of Health (NIH')s age criteria, which defines an adult as individuals aged 21 years and over. There are no restrictions related to performance status or life expectancy. * All subjects must have the ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors